Variant Creutzfeldt-Jakob disease and exposure to fractionated plasma products

Vox Sanguinis

Volumn 97, Issue 3, 2009, Pages 207-210

  Ward, H J T ^a   MacKenzie, J M ^a   Llewelyn, C A ^b   Knight, R S G ^a   Hewitt, P E ^b   Connor, N ^c   Molesworth, A ^c   Will, R G ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Fractionated plasma products; Public health; Transfusion; VCJD

Indexed keywords

ALBUMIN; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; RHESUS D ANTIBODY;

ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DISEASE COURSE; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MEDICAL RECORD; PRIORITY JOURNAL; RISK ASSESSMENT;

CHEMICAL FRACTIONATION; CREUTZFELDT-JAKOB SYNDROME; FEMALE; GAMMA-GLOBULINS; GREAT BRITAIN; HUMANS; MALE; PLASMA; PROBABILITY; RHO(D) IMMUNE GLOBULIN; RISK;

EID: 70349542922     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2009.01205.x     Document Type: Article

References (11)

1. Variant CJD and plasma products : Health Protection Agency. Available at http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb-C/1195733818681?p= 1225960597236 [Accessed 31 March 2009]
2. Llewelyn CA, Hewitt PE, Knight RSG, Amar K, Cousens S, Mackenzie J, Will RG : Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004 363 : 417 421
3. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW : Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004 364 : 527 529
4. Health Protection Agency : Fourth case of transfusion-associated variant-CJD. Health Protection Report 2007, 1. Available at http://www.hpa.org. uk/hpr/archives/2007/hpr0307.pdf [Accessed 8 June 2009]
5. Wroe SJ, Pal S, Siddique D, Hyare H, Macfarlane R, Joiner S, Linehan JM, Brandner S, Wadsworth JD, Hewitt P, Collinge J : Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 2006 368 : 2061 2067
6. Brown P, Cervenakova L, McShane LM, Barber P, Rubenstein R, Drohan WN : Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999 39 : 1169 1178
7. Foster PR : Removal of TSE agents from blood products. Vox Sang 2004 87 (Suppl. 2 S7 S10
8. Gregori L, Gurgel PV, Lathrop JT, Edwardson P, Lambert BC, Carbonell RG, Burton SJ, Hammond DJ, Rohwer RG : Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins. Lancet 2006 368 : 2226 2230
9. Risk of Infection from variant CJD in Blood : Det Norske Veritas Consulting, April 2004. Available at http://www.dnv.com/news-events/news/2004/ riskofinfectionfromvariantcjdinblood.asp [Accessed 18 November 2008]
10. Ward HJT, Everington D, Cousens SN, Smith-Bathgate B, Leitch M, Cooper S, Heath C, Knight RSG, Smith PG, Will RG : Risk factors for variant Creutzfeldt-Jakob disease: a case-control study. Ann Neurol 2006 59 : 111 120
11. Haemolytic disease of the fetus and newborn in, Klein HG, Anstee DJ (eds) : Mollison's Blood Transfusion in Clinical Medicine, 11th edn. Oxford, Blackwell Science, 2005 : 504